Clinical Scorecard: DCIS and Active Monitoring: When Immediate Surgery May Not Be the Only Conversation

At a Glance

Key Highlights

• Active monitoring may be a viable alternative to immediate surgery for selected low-risk DCIS patients.
• The COMET trial showed noninferiority of active monitoring compared to guideline-concordant care.
• Risk stratification is essential for determining eligibility for active monitoring.
• Structured surveillance with predefined escalation pathways is required for active monitoring.
• Surgery remains integral to DCIS management but may be individualized for low-risk patients.

Guideline-Based Recommendations

Diagnosis

• Use imaging to identify suitable candidates for active monitoring.
• Assess pathologic factors such as nuclear grade and hormone status.

Management

• Consider active monitoring for low-risk DCIS patients.
• Discuss the potential for individualized timing of surgery.

Monitoring & Follow-up

• Conduct diagnostic mammography every six months for the affected breast.
• Monitor for new clinical or imaging abnormalities that may require intervention.

Risks

• Mammographic stability does not guarantee biological certainty regarding disease progression.

Patient & Prescribing Data

Women with low-risk DCIS diagnosed through screening mammography.

Active monitoring may reduce overtreatment in low-risk cases.

Clinical Best Practices

• Engage in shared decision-making with patients regarding treatment options.
• Provide clear explanations about the nature of DCIS and the rationale for monitoring.

Related Resources & Content

• COMET Trial